Abeona Therapeutics received FDA approval, enabling commercial launch and securing an NDRA agreement for expedited coverage from CMS.
3 reports, 3 independent
Updated Aug 4
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Abeona Therapeutics received FDA approval, enabling commercial launch and securing an NDRA agreement for expedited coverage from CMS.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.NTAP status supports patient access and treatment economics for Abeona's therapy.1 source
- Abeona Therapeutics' therapy launch is being supported by a HUB partnership and patient-centric solutions.Sub-event
Abeona Therapeutics receives FDA approval and CMS agreement for commercial launch.1 source
Keep exploring
The entities involved
-
Abeona Therapeutics
biopharmaceutical company
Nothing else this week.
- FDA
-
Centers for Medicare and Medicaid Services
United States federal agency
Nothing else this week.
Related events
- FDA approval supports NDA submission in Aurora.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Generic medicine services are seeking approval for launch from the FDA.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- FDA approval expands patient access to therapies for ACCORD.
Coverage
Newest first; wire copies grouped- manilatimes.net
- Zacks Small Cap ResearchABEO: First Patient Treatment with Zevaskyn Expected in 3Q25… By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Commercial Launch of Zevaskyn® On-Track; First Patient
- GlobeNewswireAbeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene